Evidence map›Paper›PMID 29854294›Full record

ArticleOncotarget2018

FSH receptor binding inhibitor impacts K-Ras and c-Myc of ovarian cancer and signal pathway.

Suocheng Wei, Xiaoyun Shen, Luju Lai, Haoqin Liang, Yingying Deng, Zhuandi Gong, Tuanjie Che

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. The Role of the Guanosine Nucleotide-Binding Protein in the Corpus Luteum.Animals : an open access journal from MDPI · 2021
    Review
  4. Article
  5. FSH receptor binding inhibitor up-regulates ARID1A and PTEN genes associated with ovarian cancers in mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Suocheng Wei *College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, P. R. China.
Xiaoyun Shen *School of Karst Science, Guizhou Normal University, Guiyang, 550001, P. R. China.
Luju LaiCollege of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, P. R. China.
Haoqin LiangResearch Center of Animal Cell Engineering and Technology of Gansu Province, Northwest Minzu University, Lanzhou, 730030, P. R. China.
Yingying DengResearch Center of Animal Cell Engineering and Technology of Gansu Province, Northwest Minzu University, Lanzhou, 730030, P. R. China.
Zhuandi GongMedicine College, Northwest Minzu University, Lanzhou, 730030, P. R. China.
Tuanjie CheKey Laboratory of Functional Genomic and Molecular Diagnosis of Gansu Province, Lanzhou, 730030, P. R. China.
Minzu University of China · CNGuizhou Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to investigate FSHreceptor binding inhibitor (FRBI) effects on relative factors (K-Ras, c-Myc and Vascular endothelial growth factor (VEGF)) to ovarian cancer, and expression levels of FSH receptor (FSHR) mRNAs and proteins in the cumulus-oocyte complex (COCs), to determine changes of protein kinase A (PKA) in sheep granulosa cells, further to elucidate signaling pathway of FRBI action. COCs were cultured

Indexed as

FSH receptor binding inhibitorK-Rasoocyteovarian cancersignal pathway

Identifiers

PMID29854294
PMCPMC5976480
OpenAlexW2801797918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.